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The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy We read with interest the article by Khaleel and colleagues reporting a new prognostic signature in hormone receptor (HR)-positive breast cancer based on mRNA expression of target genes of the E2F4 transcription factor [1] . The clinical relevance comes from its independent prognostic value and its biological significance (mainly regulation of cell cycle and proliferation, reflecting high E2F4 activity − tumors (12% pCR rate). High-risk tumors were associated (Additional file 2) with ductal type, grade 3, and higher pCR rate, which was 17% versus 8% in the low-risk tumors (P <0.001). As expected, grade 3 was also associated with higher pCR rate ( Table 1) . In multivariate analysis, the E2F4 metagene remained predictive for pCR (P = 0.027), whereas grade did not. Interestingly, mRNA expression of E2F4 itself did not predict for the response to chemotherapy, demonstrating the interest of the metagene as a better indicator of E2F4 function than E2F4 expression level alone. HR + /HER2 − tumors with an E2F4 high-risk signature were more sensitive to anthracycline-based chemotherapy than low-risk tumors, as already reported with other prognostic signatures [2, 3] -including in the adjuvant setting [4, 5] , where high-risk tumors showed greater benefit from chemotherapy than low-risk tumors. The next step will be to test, retrospectively in randomized prospective trials of adjuvant chemotherapy, the hypothesis that the difference in relapse between patients treated with chemotherapy and untreated patients is larger in the high-risk group than in the low-risk group. Interest in the E2F4 signature is probably higher than expected.
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Additional file 1: Table S1 . Presenting a description of the eight public breast cancer datasets.
Additional file 2: Table S2 . Presenting the E2F4 metagene-based classification and clinicopathological correlations. 
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